Advanced lymphocyte-rich classical hodgkin lymphoma complicated with fatal hemophagocytic syndrome

3Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Lymphocyte-rich classical Hodgkin lymphoma (LRCHL) is a rare subtype of Hodgkin lymphoma with a favorable prognosis, and an aggressive clinical course of LRCHL is uncommon. A 55-year-old man suffering from swelling in the left neck was diagnosed with LRCHL with extranodal lesions in the lung and bone marrow. Initially, he received standard ABVD chemotherapy; however, disease progression, accompanied by hemophagocytic syndrome (HPS), occurred during the second course of ABVD. He received two subsequent courses of intensive chemotherapy containing high-dose steroids, cyclophosphamide, and etoposide. Nevertheless, this therapy was only temporarily effective, and he died of due to an aggressive disease progression accompanied by uncontrollable HPS and severe coagulopathy.

Cite

CITATION STYLE

APA

Ichikawa, S., Takahashi, T., Katsushima, H., Fukuhara, N., Ichinohasama, R., & Harigae, H. (2016). Advanced lymphocyte-rich classical hodgkin lymphoma complicated with fatal hemophagocytic syndrome. Internal Medicine, 55(2), 191–196. https://doi.org/10.2169/internalmedicine.55.5942

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free